Screener / SEC EDGAR /CIK 0001802768 /10-K filed Feb 11, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Royalty Pharma plc RPRX

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What RPRX's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

oyalty Pharma reports third quarter 2026 results

Open on SEC

Portfolio Receipts growth of9%to$890 million; RoyaltyReceipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million

— Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.

“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra. Lastly, we remain excited by the potential for R&D co-funding with global biopharma - where we have announced $1 billion of transactions so far this year - which represents an important new opportunity for our business. Looking ahead, with a robust deal pipeline and strong fundamental tailwinds supporting our business, we remain well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth.”

• Royalty Receipts grew 9% to $883 million, driven by Tremfya, Voranigo, Evrysdi and Imdelltra.

• Portfolio Receipts increased by 9% to $890 million, reflecting higher milestones and other contractual receipts.

• Acquired a royalty on Arcutis Biotherapeutics’ Zoryve for $100 million and on Takeda’s Mimrylo for $100 million.

• Announced value of transactions of $1.9 billion and Capital Deployment of $1.6 billion as of November 3, 2026.

• FDA approvals for Revolution Medicines’ Rasonque (daraxonrasib) for metastatic pancreatic cancer, Teva’s Weltruza (olanzapine LAI) for schizophrenia and Jazz and BeOne’s Ziihera for HER2+ metastatic gastric cancer.

• Positive Phase 3 results for Amgen’s Imdelltra as a first-line maintenance therapy for small cell lung cancer and Pharvaris’ deucrictibant XR for prophylaxis of hereditary angioedema attacks.

Raising financial guidance for full year 2026 (excludes contribution from future transactions)

• Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,500 million and $3,550 million (previously $3,400 million to $3,500 million), representing expected Royalty Receipts growth of 10% to 11%.

Three Months Ended September 30, ($ and shares in millions; 2026 2025 Change unaudited) Portfolio Receipts 890 814 9% Net cash provided by operating 686 703 (2)% activities Adjusted EBITDA (non-GAAP)* 840 779 8% Portfolio Cash Flow 673 657 2% (non-GAAP)* Weighted average Class A ordinary shares 557 560 (0)% outstanding - diluted

*See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows:

Provided November 4, 2026 Previous ────────────────────────────────────────────────────────────────────────────── Portfolio Receipts $3,500 million to $3,400 million to $3,550 million $3,500 million Payments for operating 5.5% to 6.0% of 5.5% to 6.5% of and professional Portfolio Receipts Portfolio Receipts costs Interest paid $350 million to $360 $350 million to $360 million million

Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. The above Portfolio Receipts guidance provided on November 4, 2026 includes expected Royalty Receipts growth of 10% to 11% in 2026.

Royalty Pharma’s full year 2026 guidance reflects an estimated foreign exchange impact of approximately +1% to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2026.

Payments for operating and professional costs in 2026 are expected to decrease as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due to extinguishment of the management fee following the completion of the internalization transaction on May 16, 2025.

Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and the quarterly interest payment schedules for the term loan assumed as part of the internalization transaction and borrowings under our revolving credit facility. In 2026, Royalty Pharma anticipates interest paid to be approximately $350 million to $360 million. Interest paid is anticipated to be a de minimis amount in the fourth quarter of 2026. These projections assume no additional debt financing in 2026. In the third quarter of 2026, Royalty Pharma collected interest of $6 million on its cash and cash equivalents, which partially offset interest paid.

Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.

Three Months Ended September 30, ($ in millions; 2026 2025 Change unaudited) Products: Marketers: Therapeutic Area: Cystic Rare fibrosis Vertex disease 225 222 1% franchise Trelegy GSK Respiratory 89 96 (6)% Tremfya Johnson & Immunology 80 49 61% Johnson Evrysdi Roche Rare 71 52 38% disease Tysabri Biogen Neuroscien… 67 68 (1)% Voranigo Servier Oncology 55 33 65% Xtandi Pfizer, Oncology 51 50 3% Astellas AbbVie, Imbruvica Johnson & Oncology 31 41 (24)% Johnson Exelixis, Cabometyx/… Ipsen, Oncology 24 21 13% Takeda Imdelltra Amgen Oncology 19 — n/a Trodelvy Gilead Oncology 16 12 30% Spinraza Biogen Rare 14 14 0% disease Amvuttra Alnylam Rare 10 — n/a disease Promacta Novartis Hematology 9 38 (75)% Other 121 114 6% products(5) Royalty 883 811 9% Receipts Milestones and other 7 3 138% contractual receipts Portfolio 890 814 9% Receipts

was $883 million in the third quarter of 2026, an increase of 9% compared to $811 million in the third quarter of 2025. The increase was primarily driven by Tremfya, Voranigo, Evrysdi and Imdelltra, partially offset by declines from Promacta due to U.S. generic competition and from Imbruvica. Royalty Receipts from Evrysdi included the benefit of the additional royalties acquired in December 2025.

was $890 million in the third quarter of 2026, an increase of 9% compared to $814 million in the third quarter of 2025, primarily driven by the same Royalty Receipts increases noted above, in addition to higher Milestones and other contractual receipts.

As of September 30, 2026, Royalty Pharma had cash and cash equivalents of $514 million and total debt with principal value of $8.8 billion. The reduction in total debt from $9.2 billion as of June 30, 2026 reflects payment of the $380 million term loan in July 2026.

In the third quarter of 2026, Royalty Pharma paid a quarterly dividend of $0.235 per share, equating to $135 million in dividends and distributions.

Royalty Pharma repurchased approximately 1.5 million Class A ordinary shares for $87 million in the third quarter and 3.5 million Class A ordinary shares for $183 million during the first nine months of 2026. The weighted-average number of diluted Class A ordinary shares outstanding for the third quarter of 2026 was 557 million as compared to 560 million for the third quarter of 2025.

Three Months Ended September 30, ($ in millions; unaudited) 2026 2025 Portfolio Receipts 890 814 Payments for operating and professional -50 -34 costs Adjusted EBITDA (non-GAAP) 840 779 Interest paid, net -167 -123 Portfolio Cash Flow (non-GAAP) 673 657

was $840 million in the third quarter of 2026. Payments for operating and professional costs were 5.6% of Portfolio Receipts. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs.

was $673 million in the third quarter of 2026. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.

Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $362 million in the third quarter of 2026, consisting primarily of R&D funding for JNJ‑4804 and upfront payments for cliramitug, Zoryve and Mimrylo (see 'Royalty Transactions'). Capital Deployment was $1.2 billion for the nine months ended September 30, 2026, with the announced value of transactions of $1.9 billion.

Three Months Nine Months Ended September Ended September 30, 30, ($ in millions; 2026 2025 2026 2025 unaudited) Purchases of available for — — — -75 sale debt securities Acquisitions of financial -279 -962 -982 -964 royalty assets Development-st… funding -70 -51 -193 -402 payments Milestone -13 — -63 -269 payments Contributions from legacy — -0 — 0 non-controlling interests - R&D Capital -362 -1,013 -1,239 -1,709 Deployment

As of November 3, 2026, Royalty Pharma has announced new transactions of up to $1.9 billion, which reflects the entire amount of potential capital committed for new transactions, including potential future milestones. In the third quarter of 2026, the following transactions were announced:

• In September 2026, Royalty Pharma acquired a royalty interest in Zoryve from AstraZeneca for $100 million upfront. Zoryve, marketed by Arcutis Biotherapeutics, is a topical phosphodiesterase type 4 (PDE4) inhibitor approved for atopic dermatitis, seborrheic dermatitis and plaque psoriasis.

• In August 2026, Royalty Pharma acquired a royalty interest in Mimrylo, formerly known as rusfertide, from Zealand Pharma for $100 million, consisting of $50 million paid upfront and the remaining $50 million payable on the first anniversary of the closing. Marketed by Takeda, Mimrylo is a first-in-class therapy approved for polycythemia vera, a rare and chronic blood disorder.

• In July 2026, Royalty Pharma acquired a portion of Neurimmune AG’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 first-in-class transthyretin (TTR)-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy, a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart.

The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com .

The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

In October 2026, Novartis announced that the regulatory submission for pelabresib in pelabresib myelofibrosis was completed in the European Union, based on the positive Phase 3 MANIFEST-2 study. In October 2026, Revolution Medicines announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. In October 2026, Royalty Pharma funded the required first $250 million tranche of the up to $750 million senior secured term loans to Revolution Medicines. Additionally, Revolution Medicines elected not to exercise its option for Rasonque (daraxonrasib) the third royalty funding tranche (which was up to $250 million). Up to an additional $500 million may be available at Revolution Medicines’ option under each of the senior secured term loan and royalty funding agreement, based on the achievement of certain milestones. In August 2026, Revolution Medicines announced that the U.S. Food and Drug Administration (FDA) approved Rasonque for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. In October 2026, Syndax Pharmaceuticals (Syndax) announced that the Phase 2 MAXPIRe trial of Niktimvo in idiopathic pulmonary fibrosis (IPF) Niktimvo did not meet its primary endpoint. Syndax does not plan to move forward with further development in IPF. The results do not affect ongoing trials of Niktimvo in other indications. In October 2026, Teva Pharmaceuticals (Teva) announced that the FDA approved Weltruza for Weltruza (TEV-’749) extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. In September 2026, Roche announced that Phase 3 trontinemab studies of trontinemab in early Alzheimer’s disease have fully enrolled, with data expected in the first half of 2028. In September 2026, Amgen announced positive results from the Phase 3 DeLLphi-305 study of Imdelltra in combination with Imfinzi as first-line maintenance treatment for extensive-stage small cell lung cancer. The study Imdelltra met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival, and also met secondary endpoints of progression-free survival and objective response rate.

In September 2026, Pharvaris announced positive results from the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release for the prevention of hereditary angioedema (HAE) attacks. The primary endpoint and all secondary efficacy endpoints were met with statistical significance. In July 2026, Pharvaris announced that the FDA accepted its New Drug Application (NDA) for deucrictibant immediate-release for the on-demand treatment of HAE attacks and assigned a Prescription Drug User Fee Act (PDUFA) date of April 23, 2027. In September 2026, Novartis announced that the Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events in the overall study population compared to placebo. In the third quarter of 2026, Royalty Pharma recorded a non-cash deucrictibant impairment charge of $150 million pelacarsen related to pelacarsen. ────────────────────────────────────────────────────────────────────────────── In September 2026, Teva announced positive topline results from an ongoing Phase 2a study of TEV-’408, an anti-IL-15 antibody, in adults with celiac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of TEV-’408 gluten-induced intestinal damage versus placebo at week 8, and was well tolerated, with no safety signals observed to date. In July 2026, Teva announced plans to advance TEV-’408 into a Phase 2b study in patients with non-segmental vitiligo, following positive Phase 1b results. In August 2026, Takeda announced that the FDA approved Mimrylo, a Mimrylo (rusfertide) hepcidin mimetic peptide, for the treatment of erythrocytosis in adults with polycythemia vera. In August 2026, Jazz Pharmaceuticals announced that the FDA approved Ziihera in combination with chemotherapy, with or without Ziihera tislelizumab, for the first-line treatment of adults with metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma. In August 2026, Gilead announced that the European Commission approved Trodelvy in combination Trodelvy with Keytruda as a first-line treatment for PD-L1-positive metastatic triple-negative breast cancer. In August 2026, Teva announced that the FDA accepted its NDA for ecopipam for the treatment of ecopipam pediatric Tourette syndrome and granted the application Priority Review with a PDUFA date late in the first quarter of 2027. In August 2026, Zenas BioPharma announced that the FDA accepted for review its Biologics License obexelimab Application for obexelimab for the treatment of immunoglobulin G4-related disease (IgG4-RD) and assigned a PDUFA target action date of May 27, 2027. In July 2026, GSK announced that the FDA approved Jideytro, a ROS proto-oncogene 1 (ROS1)-selective inhibitor, for the treatment of adult patients with metastatic ROS1-positive non-small cell lung cancer who have received a prior Jideytro (zidesamtinib) and ROS1 kinase inhibitor. neladalkib In July 2026, GSK announced that it completed the acquisition of Nuvalent for approximately $10.6 billion, including Jideytro and neladalkib, two highly selective ROS1 and anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.

Royalty Pharma will host a conference call and simultaneous webcast to discuss its third quarter of 2026 results today at 8:00 a.m. Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top- line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 16 development-stage product candidates.

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.

Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy. 2025 Portfolio Receipts does not include the $511 million of proceeds from the sale of the MorphoSys Development Funding Bonds, as the transaction was treated as an asset sale.

Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities a nd Distributions from equity method investees less Distributions to legacy non-controlling interests - Portfolio Receipts , which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.

The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.

Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.

The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.

Three Months Ended September 30, ($ in millions) 2026 2025 Income and other revenues Income from financial royalty 648 579 assets Other royalty income and 42 30 revenues Total income and other revenues 690 609 Operating (income)/expense Provision for changes in expected cash -88 12 flows from financial royalty assets Provision for credit losses on unfunded 4 1 commitments Research and development funding 63 51 expense General and administrative expenses (includes 105 and 73 of share-based compensation expense for the 150 119 three months ended September 30, 2026 and 2025, respectively) Financial royalty asset 150 — impairment Total operating expense, net 279 182 Operating income 411 427 Other (income)/expense Equity in earnings of equity method -9 -16 investees Interest expense 90 80 Other expense/(income), net 63 -77 Total other expense/(income), 144 -13 net Consolidated net income before 267 440 tax Income tax expense — — Consolidated net income 267 440 Net income attributable to 122 156 non-controlling interests Net income attributable to Royalty 145 284 Pharma plc

Three Months Nine Months Ended September Ended September 30, 30, ($ in millions) 2026 2025 2026 2025 Cash flows from operating activities: Cash collections from financial 930 882 2,660 2,439 royalty assets Cash collections from intangible 0 0 4 1 royalty assets Other royalty cash 38 29 104 85 collections Distributions from equity 8 — 33 13 method investees Interest 6 7 18 28 received Development-st… funding -70 -51 -193 -402 payments Payments for operating and -50 -34 -123 -230 professional costs Payments for -3 -2 -18 -2 Employee EPAs Interest paid -173 -130 -352 -270 Net cash provided by 686 703 2,133 1,663 operating activities Cash flows from investing activities: Acquisition of businesses, net — -0 — -74 of cash acquired Distributions from equity 1 1 30 100 method investees Purchases of equity — — -28 -4 securities Proceeds from equity — — 36 — securities Purchases of available for — — — -75 sale debt securities Proceeds from available for 6 3 14 18 sale debt securities Proceeds from sales of available for — — — 511 sale debt securities Acquisitions of financial -279 -962 -982 -964 royalty assets Milestone -13 — -63 -269 payments Other -0 — -1 -9 Net cash used in investing -286 -958 -993 -766 activities Cash flows from financing activities: Distributions to legacy non-controlling -93 -102 -257 -276 interests - Portfolio Receipts Distributions to continuing -33 -34 -108 -127 non-controlling interests Dividends to -105 -95 -315 -284 shareholders Repurchases of Class A -86 -146 -181 -1,147 ordinary shares Contributions from legacy — -0 — 0 non-controlling interests - R&D Contributions from non-controlling — 0 — 6 interests - other Proceeds from revolving 50 1,275 50 1,275 credit facility Repayment of revolving -50 -1,275 -50 -1,275 credit facility Repayment of -380 -1,000 -380 -1,000 long-term debt Proceeds from issuance of long-term — 1,954 — 1,954 debt, net of discount Debt issuance 0 -14 -2 -14 costs and other Other -1 — -2 — Net cash (used in)/provided by -699 563 -1,245 -886 financing activities Net change in cash and cash -298 307 -105 10 equivalents Cash and cash equivalents, 812 632 619 929 beginning of period Cash and cash equivalents, 514 939 514 939 end of period

Three Months Ended September 30, ($ in millions) 2026 2025 Net cash provided by operating 686 703 activities (GAAP) Adjustments: Proceeds from available for sale debt 6 3 securities(6) Distributions from equity method 1 1 investees(6) Interest paid, net(6) 167 123 Development-stage funding 70 51 payments Distributions to legacy non-controlling -93 -102 interests - Portfolio Receipts(6) Payments for Employee EPAs 3 2 Adjusted EBITDA (non-GAAP) 840 779 Interest paid, net(6) -167 -123 Portfolio Cash Flow (non-GAAP) 673 657

Cystic fibrosis franchise Cystic fibrosis Trelegy Chronic obstructive pulmonary disease and asthma Tremfya Plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease Evrysdi Spinal muscular atrophy Tysabri Relapsing forms of multiple sclerosis Voranigo Low-grade glioma Xtandi Prostate cancer Imbruvica Hematological malignancies and chronic graft versus host disease Cabometyx/Cometriq Kidney, liver and thyroid cancer Imdelltra Small cell lung cancer Trodelvy Breast cancer Spinraza Spinal muscular atrophy Amvuttra Transthyretin amyloidosis Promacta Chronic immune thrombocytopenia purpura and aplastic anemia

(1) Portfolio Receipts is defined above in the section entitled “Portfolio Receipts.”

(2) Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP condensed consolidated statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.

(3) Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.

(4) Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments and Development-stage funding payments less Contributions from legacy non-controlling interests - R&D .

(5) Other products primarily include Royalty Receipts on the following products: Crysvita, Erleada, Farxiga/Onglyza, IDHIFA, Niktimvo, Nurtec ODT, Orladeyo, Prevymis, Skytrofa, Yorvipath and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP condensed consolidated statements of cash flows.

(6) The table below shows the line item for each adjustment and the direct location for such line item on the GAAP condensed consolidated statements of cash flows.

Reconciling Adjustment Statements of Cash Flows Classification Interest paid, net Operating activities(Interest paidlessInterest received) Distributions from equity method Investing activities investees Proceeds from available for sale debt Investing activities securities Distributions to legacy non-controlling Financing activities interests - Portfolio Receipts

(7) The condensed consolidated statement of operations for 2025 has been recast to reflect the adoption of ASU 2025-07 by removing the gains previously recognized on derivative.

Full text with the tables
                    
  Press Release     
  November 4, 2026  
 ────────────────── 
                    
R
                                                                                
   oyalty Pharma reports third quarter 2026 results                             
                                                                                
                                                     
  Portfolio Receipts growth of9%to$890 million;      
  RoyaltyReceipts growth of 9%                       
  Net cash provided by operating activities of $686  
  million                                            
  Raised full year 2026 guidance:                    
  Portfolio Receipts expected to be $3,500 million   
  to $3,550 million                                  
                                                     
                                                                                
  NEW YORK, NY, November 4, 2026                                                
                                                                                
— Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the
third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.
                                                      
  “Royalty Pharma delivered excellent third quarter   
  2026 results and we again raised our financial      
  guidance,” said Pablo Legorreta, Royalty Pharma’s   
  Chief Executive Officer and Chairman of the Board.  
  “We delivered 9% growth in Royalty Receipts for     
  the quarter and double-digit growth year-to-date.   
  We continued to strengthen our portfolio by adding  
  royalties on three innovative therapies in the      
  third quarter. We have also seen tremendous         
  clinical and regulatory progress across our         
  portfolio, including FDA approvals of Revolution    
  Medicines’ Rasonque and Teva’s Weltruza and         
  positive Phase 3 results for Amgen’s Imdelltra.     
  Lastly, we remain excited by the potential for R&D  
  co-funding with global biopharma - where we have    
  announced $1 billion of transactions so far this    
  year - which represents an important new            
  opportunity for our business. Looking ahead, with   
  a robust deal pipeline and strong fundamental       
  tailwinds supporting our business, we remain well   
  positioned as a premier capital allocator in life   
  sciences to deliver consistent, compounding         
  growth.”                                            
                                                      
Strong growth in Royalty Receipts in the third quarter of 2026

• Royalty Receipts grew 9% to $883 million, driven by Tremfya, Voranigo, Evrysdi
and Imdelltra.

• Portfolio Receipts increased by 9% to $890 million, reflecting higher
milestones and other contractual receipts.
                                                                                
  Continued healthy transaction activity                                        
                                                                                
• Acquired a royalty on Arcutis Biotherapeutics’ Zoryve for $100 million and on
Takeda’s Mimrylo for $100 million.

• Announced value of transactions of $1.9 billion and Capital Deployment of $1.6
billion as of November 3, 2026.

Positive regulatory and clinical updates across royalty portfolio

• FDA approvals for Revolution Medicines’ Rasonque (daraxonrasib) for metastatic
pancreatic cancer, Teva’s Weltruza (olanzapine LAI) for schizophrenia and Jazz
and BeOne’s Ziihera for HER2+ metastatic gastric cancer.

• Positive Phase 3 results for Amgen’s Imdelltra as a first-line maintenance
therapy for small cell lung cancer and Pharvaris’ deucrictibant XR for
prophylaxis of hereditary angioedema attacks.

Raising financial guidance for full year 2026 (excludes contribution from future
transactions)

• Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,500
million and $3,550 million (previously $3,400 million to $3,500 million),
representing expected Royalty Receipts growth of 10% to 11%.

Financial & Liquidity Summary
                                                                                
                                          Three Months Ended                    
                                               September 30,                    
  ($ and shares in millions;                            2026    2025    Change  
  unaudited)                                                                    
  Portfolio Receipts                                     890     814    9%      
  Net cash provided by                                                          
  operating                                              686     703    (2)%    
  activities                                                                    
  Adjusted EBITDA (non-GAAP)*                            840     779    8%      
  Portfolio Cash Flow                                    673     657    2%      
  (non-GAAP)*                                                                   
  Weighted average Class A                                                      
  ordinary shares                                        557     560    (0)%    
  outstanding - diluted                                                         
                                                                                
*See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio
Cash Flow are non-GAAP liquidity measures calculated in accordance with the
credit agreement.
                                                       
  Royalty Pharma Press Release| November 4, 2026    1  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
   2026 Financial Outlook                                                       
                                                                                
Royalty Pharma has provided guidance for full year 2026, excluding new
transactions and borrowings announced after the date of this release, as
follows:
                                                                                
                            Provided November 4,                                
                            2026                       Previous                 
 ────────────────────────────────────────────────────────────────────────────── 
  Portfolio Receipts        $3,500 million to          $3,400 million to        
                            $3,550 million             $3,500 million           
  Payments for operating    5.5% to 6.0% of            5.5% to 6.5% of          
  and professional          Portfolio Receipts         Portfolio Receipts       
  costs                                                                         
  Interest paid             $350 million to $360       $350 million to $360     
                            million                    million                  
                                                                                
Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and
other contractual receipts. The above Portfolio Receipts guidance provided on
November 4, 2026 includes expected Royalty Receipts growth of 10% to 11% in
2026.

Royalty Pharma’s full year 2026 guidance reflects an estimated foreign exchange
impact of approximately +1% to Portfolio Receipts, assuming current foreign
exchange rates prevail for the rest of 2026.

Payments for operating and professional costs in 2026 are expected to decrease
as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due
to extinguishment of the management fee following the completion of the
internalization transaction on May 16, 2025.

Total interest paid is based on the semi-annual interest payment schedule of
Royalty Pharma’s existing notes and the quarterly interest payment schedules for
the term loan assumed as part of the internalization transaction and borrowings
under our revolving credit facility. In 2026, Royalty Pharma anticipates
interest paid to be approximately $350 million to $360 million. Interest paid is
anticipated to be a de minimis amount in the fourth quarter of 2026. These
projections assume no additional debt financing in 2026. In the third quarter of
2026, Royalty Pharma collected interest of $6 million on its cash and cash
equivalents, which partially offset interest paid.

Royalty Pharma today provides this guidance based on its most up-to-date view of
its prospects. This guidance assumes no major unforeseen adverse events or
changes in foreign exchange rates and excludes the contributions from
transactions announced subsequent to the date of this press release.
                                                       
  Royalty Pharma Press Release| November 4, 2026    2  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
  Portfolio Receipts Highlights                                                 
                                                                                
                                                                                
                                                Three Months                    
                                                       Ended                    
                                                   September                    
                                                         30,                    
  ($ in                                                                         
  millions;                                             2026    2025    Change  
  unaudited)                                                                    
  Products:      Marketers:      Therapeutic                                    
                                 Area:                                          
  Cystic                         Rare                                           
  fibrosis       Vertex          disease                 225     222    1%      
  franchise                                                                     
  Trelegy        GSK             Respiratory              89      96    (6)%    
  Tremfya        Johnson &       Immunology               80      49    61%     
                 Johnson                                                        
  Evrysdi        Roche           Rare                     71      52    38%     
                                 disease                                        
  Tysabri        Biogen          Neuroscien…              67      68    (1)%    
  Voranigo       Servier         Oncology                 55      33    65%     
  Xtandi         Pfizer,         Oncology                 51      50    3%      
                 Astellas                                                       
                 AbbVie,                                                        
  Imbruvica      Johnson &       Oncology                 31      41    (24)%   
                 Johnson                                                        
                 Exelixis,                                                      
  Cabometyx/…    Ipsen,          Oncology                 24      21    13%     
                 Takeda                                                         
  Imdelltra      Amgen           Oncology                 19       —    n/a     
  Trodelvy       Gilead          Oncology                 16      12    30%     
  Spinraza       Biogen          Rare                     14      14    0%      
                                 disease                                        
  Amvuttra       Alnylam         Rare                     10       —    n/a     
                                 disease                                        
  Promacta       Novartis        Hematology                9      38    (75)%   
  Other                                                  121     114    6%      
  products(5)                                                                   
  Royalty                                                883     811    9%      
  Receipts                                                                      
  Milestones                                                                    
  and other                                                7       3    138%    
  contractual                                                                   
  receipts                                                                      
  Portfolio                                              890     814    9%      
  Receipts                                                                      
                                                                                
Amounts shown in the table may not add due to rounding.
                                                                                
  Royalty Receipts                                                              
                                                                                
was $883 million in the third quarter of 2026, an increase of 9% compared to
$811 million in the third quarter of 2025. The increase was primarily driven by
Tremfya, Voranigo, Evrysdi and Imdelltra, partially offset by declines from
Promacta due to U.S. generic competition and from Imbruvica. Royalty Receipts
from Evrysdi included the benefit of the additional royalties acquired in
December 2025.
                                                                                
  Portfolio Receipts                                                            
                                                                                
was $890 million in the third quarter of 2026, an increase of 9% compared to
$814 million in the third quarter of 2025, primarily driven by the same Royalty
Receipts increases noted above, in addition to higher Milestones and other
contractual receipts.
                                                       
  Royalty Pharma Press Release| November 4, 2026    3  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
   Liquidity and Capital Resources                                              
                                                                                
Royalty Pharma’s liquidity and capital resources are summarized below:

As of September 30, 2026, Royalty Pharma had cash and cash equivalents of $514
million and total debt with principal value of $8.8 billion. The reduction in
total debt from $9.2 billion as of June 30, 2026 reflects payment of the $380
million term loan in July 2026.

In the third quarter of 2026, Royalty Pharma paid a quarterly dividend of $0.235
per share, equating to $135 million in dividends and distributions.

Royalty Pharma repurchased approximately 1.5 million Class A ordinary shares for
$87 million in the third quarter and 3.5 million Class A ordinary shares for
$183 million during the first nine months of 2026. The weighted-average number
of diluted Class A ordinary shares outstanding for the third quarter of 2026 was
557 million as compared to 560 million for the third quarter of 2025.

Liquidity Summary
                                                                                
                                      Three Months Ended September 30,          
  ($ in millions; unaudited)                                      2026    2025  
  Portfolio Receipts                                               890     814  
  Payments for operating and                                                    
  professional                                                     -50     -34  
  costs                                                                         
  Adjusted EBITDA (non-GAAP)                                       840     779  
  Interest paid, net                                              -167    -123  
  Portfolio Cash Flow (non-GAAP)                                   673     657  
                                                                                
Amounts may not add due to rounding.

•
                                                                                
  Adjusted EBITDA (non-GAAP)                                                    
                                                                                
was $840 million in the third quarter of 2026. Payments for operating and
professional costs were 5.6% of Portfolio Receipts. Adjusted EBITDA is
calculated as Portfolio Receipts minus payments for operating and professional
costs.

•
                                                                                
  Portfolio Cash Flow (non-GAAP)                                                
                                                                                
was $673 million in the third quarter of 2026. Portfolio Cash Flow is calculated
as Adjusted EBITDA minus interest paid or received, net. This measure reflects
the cash generated by Royalty Pharma’s business that can be redeployed into
value-enhancing royalty acquisitions, used to repay debt, returned to
shareholders through dividends or share purchases, or utilized for other
discretionary investments.

Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to
the most directly comparable GAAP financial measure, net cash provided by
operating activities.

Capital Deployment reflects cash payments during the period for new and
previously announced transactions. Capital Deployment was $362 million in the
third quarter of 2026, consisting primarily of R&D funding for JNJ‑4804 and
upfront payments for cliramitug, Zoryve and Mimrylo (see 'Royalty
Transactions'). Capital Deployment was $1.2 billion for the nine months ended
September 30, 2026, with the announced value of transactions of $1.9 billion.

The table below details Capital Deployment by category:

Capital Deployment
                                                                                
                          Three Months                   Nine Months            
                       Ended September               Ended September            
                                   30,                           30,            
  ($ in millions;                 2026      2025                2026      2025  
  unaudited)                                                                    
  Purchases of                                                                  
  available for                      —         —                   —       -75  
  sale debt                                                                     
  securities                                                                    
  Acquisitions of                                                               
  financial                       -279      -962                -982      -964  
  royalty assets                                                                
  Development-st…                                                               
  funding                          -70       -51                -193      -402  
  payments                                                                      
  Milestone                        -13         —                 -63      -269  
  payments                                                                      
  Contributions                                                                 
  from legacy                        —        -0                   —         0  
  non-controlling                                                               
  interests - R&D                                                               
  Capital                         -362    -1,013              -1,239    -1,709  
  Deployment                                                                    
                                                                                
Amounts may not add due to rounding.
                                                       
  Royalty Pharma Press Release| November 4, 2026    4  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
  Royalty Transactions                                                          
                                                                                
As of November 3, 2026, Royalty Pharma has announced new transactions of up to
$1.9 billion, which reflects the entire amount of potential capital committed
for new transactions, including potential future milestones. In the third
quarter of 2026, the following transactions were announced:

• In September 2026, Royalty Pharma acquired a royalty interest in Zoryve from
AstraZeneca for $100 million upfront. Zoryve, marketed by Arcutis
Biotherapeutics, is a topical phosphodiesterase type 4 (PDE4) inhibitor approved
for atopic dermatitis, seborrheic dermatitis and plaque psoriasis.

• In August 2026, Royalty Pharma acquired a royalty interest in Mimrylo,
formerly known as rusfertide, from Zealand Pharma for $100 million, consisting
of $50 million paid upfront and the remaining $50 million payable on the first
anniversary of the closing. Marketed by Takeda, Mimrylo is a first-in-class
therapy approved for polycythemia vera, a rare and chronic blood disorder.

• In July 2026, Royalty Pharma acquired a portion of Neurimmune AG’s royalty
interest in AstraZeneca’s cliramitug for up to $425 million, including $125
million upfront. Cliramitug is a Phase 3 first-in-class transthyretin
(TTR)-fibril-depleting antibody designed to remove amyloid deposits in patients
with TTR amyloidosis with cardiomyopathy, a progressive, degenerative and fatal
disease caused by misfolded proteins that accumulate in the heart.

The information in this section should be read together with Royalty Pharma’s
reports and documents filed with the SEC at www.sec.gov and the reader is also
encouraged to review all other press releases and information available in the
Investors section of Royalty Pharma’s website at www.royaltypharma.com .
                                                                                
  Key Developments Relating to the Portfolio                                    
                                                                                
The key developments related to Royalty Pharma’s royalty interests are discussed
below based on disclosures from the marketers of the products.
                                                                                
                             In October 2026, Novartis announced that the       
                             regulatory submission for pelabresib in            
  pelabresib                 myelofibrosis was completed in the European        
                             Union, based on the positive Phase 3 MANIFEST-2    
                             study.                                             
                             In October 2026, Revolution Medicines announced    
                             that the European Medicines Agency’s Committee     
                             for Medicinal Products for Human Use (CHMP) had    
                             adopted a positive opinion of Rasonque for the     
                             treatment of adult patients with metastatic        
                             pancreatic adenocarcinoma who have received at     
                             least one prior systemic therapy.                  
                             In October 2026, Royalty Pharma funded the         
                             required first $250 million tranche of the up to   
                             $750 million senior secured term loans to          
                             Revolution Medicines. Additionally, Revolution     
                             Medicines elected not to exercise its option for   
  Rasonque (daraxonrasib)    the third royalty funding tranche (which was up    
                             to $250 million). Up to an additional $500         
                             million may be available at Revolution Medicines’  
                             option under each of the senior secured term loan  
                             and royalty funding agreement, based on the        
                             achievement of certain milestones.                 
                             In August 2026, Revolution Medicines announced     
                             that the U.S. Food and Drug Administration (FDA)   
                             approved Rasonque for the treatment of adults      
                             with metastatic pancreatic adenocarcinoma who      
                             have received at least one prior systemic therapy  
                             or who are not candidates for multiagent systemic  
                             therapy.                                           
                             In October 2026, Syndax Pharmaceuticals (Syndax)   
                             announced that the Phase 2 MAXPIRe trial of        
                             Niktimvo in idiopathic pulmonary fibrosis (IPF)    
  Niktimvo                   did not meet its primary endpoint. Syndax does     
                             not plan to move forward with further development  
                             in IPF. The results do not affect ongoing trials   
                             of Niktimvo in other indications.                  
                             In October 2026, Teva Pharmaceuticals (Teva)       
                             announced that the FDA approved Weltruza for       
  Weltruza (TEV-’749)        extended-release injectable suspension, a new,     
                             once-monthly, subcutaneous long-acting injectable  
                             (LAI) for the treatment of schizophrenia in        
                             adults.                                            
                             In September 2026, Roche announced that Phase 3    
  trontinemab                studies of trontinemab in early Alzheimer’s        
                             disease have fully enrolled, with data expected    
                             in the first half of 2028.                         
                             In September 2026, Amgen announced positive        
                             results from the Phase 3 DeLLphi-305 study of      
                             Imdelltra in combination with Imfinzi as           
                             first-line maintenance treatment for               
                             extensive-stage small cell lung cancer. The study  
  Imdelltra                  met its primary endpoint at a pre-specified        
                             interim analysis, demonstrating a statistically    
                             significant and clinically meaningful improvement  
                             in overall survival, and also met secondary        
                             endpoints of progression-free survival and         
                             objective response rate.                           
                                                                                
                                                       
  Royalty Pharma Press Release| November 4, 2026    5  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
                                          In September 2026, Pharvaris          
                                          announced positive results from the   
                                          CHAPTER-3 pivotal Phase 3 study       
                                          evaluating deucrictibant              
                                          extended-release for the prevention   
                                          of hereditary angioedema (HAE)        
                                          attacks. The primary endpoint and     
                                          all secondary efficacy endpoints      
                                          were met with statistical             
                                          significance.                         
                                          In July 2026, Pharvaris announced     
                                          that the FDA accepted its New Drug    
                                          Application (NDA) for deucrictibant   
                                          immediate-release for the on-demand   
                                          treatment of HAE attacks and          
                                          assigned a Prescription Drug User     
                                          Fee Act (PDUFA) date of April 23,     
                                          2027.                                 
                                          In September 2026, Novartis           
                                          announced that the Phase 3            
                                          Lp(a)HORIZON trial of pelacarsen did  
                                          not meet its primary endpoint of      
                                          reducing the risk of cardiovascular   
                                          events in the overall study           
                                          population compared to placebo. In    
                                          the third quarter of 2026, Royalty    
                                          Pharma recorded a non-cash            
  deucrictibant                           impairment charge of $150 million     
  pelacarsen                              related to pelacarsen.                
 ────────────────────────────────────────────────────────────────────────────── 
                                          In September 2026, Teva announced     
                                          positive topline results from an      
                                          ongoing Phase 2a study of TEV-’408,   
                                          an anti-IL-15 antibody, in adults     
                                          with celiac disease. The study met    
                                          its primary endpoint, demonstrating   
                                          statistically significant and         
                                          clinically meaningful prevention of   
  TEV-’408                                gluten-induced intestinal damage      
                                          versus placebo at week 8, and was     
                                          well tolerated, with no safety        
                                          signals observed to date.             
                                          In July 2026, Teva announced plans    
                                          to advance TEV-’408 into a Phase 2b   
                                          study in patients with non-segmental  
                                          vitiligo, following positive Phase    
                                          1b results.                           
                                          In August 2026, Takeda announced      
                                          that the FDA approved Mimrylo, a      
  Mimrylo (rusfertide)                    hepcidin mimetic peptide, for the     
                                          treatment of erythrocytosis in        
                                          adults with polycythemia vera.        
                                          In August 2026, Jazz Pharmaceuticals  
                                          announced that the FDA approved       
                                          Ziihera in combination with           
                                          chemotherapy, with or without         
  Ziihera                                 tislelizumab, for the first-line      
                                          treatment of adults with metastatic   
                                          human epidermal growth factor         
                                          receptor 2 (HER2)-positive            
                                          gastroesophageal adenocarcinoma.      
                                          In August 2026, Gilead announced      
                                          that the European Commission          
                                          approved Trodelvy in combination      
  Trodelvy                                with Keytruda as a first-line         
                                          treatment for PD-L1-positive          
                                          metastatic triple-negative breast     
                                          cancer.                               
                                          In August 2026, Teva announced that   
                                          the FDA accepted its NDA for          
                                          ecopipam for the treatment of         
  ecopipam                                pediatric Tourette syndrome and       
                                          granted the application Priority      
                                          Review with a PDUFA date late in the  
                                          first quarter of 2027.                
                                          In August 2026, Zenas BioPharma       
                                          announced that the FDA accepted for   
                                          review its Biologics License          
  obexelimab                              Application for obexelimab for the    
                                          treatment of immunoglobulin           
                                          G4-related disease (IgG4-RD) and      
                                          assigned a PDUFA target action date   
                                          of May 27, 2027.                      
                                          In July 2026, GSK announced that the  
                                          FDA approved Jideytro, a ROS          
                                          proto-oncogene 1 (ROS1)-selective     
                                          inhibitor, for the treatment of       
                                          adult patients with metastatic        
                                          ROS1-positive non-small cell lung     
                                          cancer who have received a prior      
  Jideytro (zidesamtinib) and             ROS1 kinase inhibitor.                
  neladalkib                              In July 2026, GSK announced that it   
                                          completed the acquisition of          
                                          Nuvalent for approximately $10.6      
                                          billion, including Jideytro and       
                                          neladalkib, two highly selective      
                                          ROS1 and anaplastic lymphoma kinase   
                                          inhibitors for the treatment of       
                                          non-small cell lung cancer.           
                                                                                
                                                                                
   Financial Results Call                                                       
                                                                                
Royalty Pharma will host a conference call and simultaneous webcast to discuss
its third quarter of 2026 results today at 8:00 a.m. Eastern Time. Please visit
the “Investors” page of the company’s website at
https://www.royaltypharma.com/investors/events to obtain conference call
information and to view the live webcast. A replay of the conference call and
webcast will be archived on the company’s website for at least 30 days.
                                                                                
  About Royalty Pharma plc                                                      
                                                                                
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical
royalties and a leading funder of innovation across the biopharmaceutical
industry, collaborating with innovators from academic institutions, research
hospitals and non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has assembled a
portfolio of royalties which entitles it to payments based directly on the top-
line sales of many of the industry’s leading therapies. Royalty Pharma’s current
portfolio includes royalties on more than 35 commercial products, including
Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza,
Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya,
AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy,
Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 16 development-stage
product candidates.
                                                       
  Royalty Pharma Press Release| November 4, 2026    6  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
  Forward-Looking Statements                                                    
                                                                                
The information set forth herein does not purport to be complete or to contain
all of the information you may desire. Statements contained herein are made as
of the date of this document unless stated otherwise, and neither the delivery
of this document at any time, nor any sale of securities, shall under any
circumstances create an implication that the information contained herein is
correct as of any time after such date or that information will be updated or
revised to reflect information that subsequently becomes available or changes
occurring after the date hereof.

This document contains statements that constitute “forward-looking statements”
as that term is defined in the United States Private Securities Litigation
Reform Act of 1995, including statements that express the company’s opinions,
expectations, beliefs, plans, objectives, assumptions or projections regarding
future events or future results, in contrast with statements that reflect
historical facts. Examples include discussion of Royalty Pharma’s strategies,
financing plans, growth opportunities, market growth and plans for capital
deployment, plus the benefits of the internalization transaction, including
expected accretion, enhanced alignment with shareholders, increased investment
returns, expectations regarding management continuity, transparency and
governance, and the benefits of simplification to its structure. In some cases,
you can identify such forward-looking statements by terminology such as
“anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,”
“expect,” “may,” “will,” “would,” “could” or “should,” the negative of these
terms or similar expressions. Forward-looking statements are based on
management’s current beliefs and assumptions and on information currently
available to the company. However, these forward-looking statements are not a
guarantee of Royalty Pharma’s performance, and you should not place undue
reliance on such statements. Forward-looking statements are subject to many
risks, uncertainties and other variable circumstances, and other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many of these
risks are outside of the company’s control and could cause its actual results to
differ materially from those it thought would occur. The forward-looking
statements included in this document are made only as of the date hereof. The
company does not undertake, and specifically declines, any obligation to update
any such statements or to publicly announce the results of any revisions to any
such statements to reflect future events or developments, except as required by
law.

Certain information contained in this document relates to or is based on
studies, publications, surveys and other data obtained from third-party sources
and the company’s own internal estimates and research. While the company
believes these third-party sources to be reliable as of the date of this
document, it has not independently verified, and makes no representation as to
the adequacy, fairness, accuracy or completeness of, any information obtained
from third-party sources. In addition, all of the market data included in this
document involves a number of assumptions and limitations, and there can be no
guarantee as to the accuracy or reliability of such assumptions. Finally, while
the company believes its own internal research is reliable, such research has
not been verified by any independent source.

For further information, please reference Royalty Pharma’s reports and documents
filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR
on the SEC’s website at www.sec.gov.
                                                                                
  Portfolio Receipts                                                            
                                                                                
Portfolio Receipts is a key performance metric that represents Royalty Pharma’s
ability to generate cash from Royalty Pharma’s portfolio investments, the
primary source of capital that is deployed to make new portfolio investments.
Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and
other contractual receipts. Royalty Receipts includes variable payments based on
sales of products, net of contractual payments to the legacy non-controlling
interests, that are attributed to Royalty Pharma.

Milestones and other contractual receipts include sales-based or regulatory
milestone payments and other fixed contractual receipts, net of contractual
payments to legacy non-controlling interests, that are attributed to Royalty
Pharma. Portfolio Receipts does not include royalty receipts and milestones and
other contractual receipts that were received on an accelerated basis under the
terms of the agreement governing the receipt or payment. Portfolio Receipts also
does not include proceeds from equity securities or proceeds from purchases and
sales of marketable securities, both of which are not central to Royalty
Pharma’s fundamental business strategy. 2025 Portfolio Receipts does not include
the $511 million of proceeds from the sale of the MorphoSys Development Funding
Bonds, as the transaction was treated as an asset sale.

Portfolio Receipts is calculated as the sum of the following line items from
Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash
collections from financial royalty assets, Cash collections from intangible
royalty assets, Other royalty cash collections, Proceeds from available for sale
debt securities a nd Distributions from equity method investees less
Distributions to legacy non-controlling interests - Portfolio Receipts , which
represent contractual distributions of Royalty Receipts, milestones and other
contractual receipts to the Legacy Investors Partnerships.
                                                       
  Royalty Pharma Press Release| November 4, 2026    7  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
  Use of Non-GAAP Measures                                                      
                                                                                
Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that
exclude the impact of certain items and therefore have not been calculated in
accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio
Cash Flow are important non-GAAP measures used to analyze liquidity because they
are key components of certain material covenants contained within Royalty
Pharma’s credit agreement. Royalty Pharma cautions readers that amounts
presented in accordance with the definitions of Adjusted EBITDA and Portfolio
Cash Flow may not be the same as similar measures used by other companies or
analysts. These non-GAAP liquidity measures have limitations as analytical
tools, and you should not consider them in isolation or as a substitute for the
analysis of Royalty Pharma’s results as reported under GAAP.

The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty
Pharma are the same as the definitions in the credit agreement. Noncompliance
with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio
covenants under the credit agreement could result in lenders requiring the
company to immediately repay all amounts borrowed. If Royalty Pharma cannot
satisfy these covenants, it would be prohibited under the credit agreement from
engaging in certain activities, such as incurring additional indebtedness,
paying dividends, making certain payments, and acquiring and disposing of
assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to
the assessment of Royalty Pharma’s liquidity.

Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity
measures in the evaluation of the company’s ability to generate cash from
operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when
considering available cash, including for decision-making purposes related to
funding of acquisitions, debt repayments, dividends and other discretionary
investments. Further, these non-GAAP liquidity measures help management, the
audit committee and investors evaluate the company’s ability to generate
liquidity from operating activities.

The company has provided reconciliations of these non-GAAP liquidity measures to
the most directly comparable GAAP financial measure, being net cash provided by
operating activities in Table 4.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772

[email protected]
                                                       
  Royalty Pharma Press Release| November 4, 2026    8  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
                               Royalty Pharma plc                               
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                                (7) (unaudited)                                 
                                                                                
                                    Table 1                                     
                                                                                
                                                                                
                                      Three Months Ended September 30,          
  ($ in millions)                                                 2026    2025  
  Income and other revenues                                                     
  Income from financial royalty                                    648     579  
  assets                                                                        
  Other royalty income and                                          42      30  
  revenues                                                                      
  Total income and other revenues                                  690     609  
  Operating (income)/expense                                                    
  Provision for changes in                                                      
  expected cash                                                    -88      12  
  flows from financial royalty                                                  
  assets                                                                        
  Provision for credit losses on                                                
  unfunded                                                           4       1  
  commitments                                                                   
  Research and development funding                                  63      51  
  expense                                                                       
  General and administrative                                                    
  expenses                                                                      
  (includes 105 and 73 of                                                       
  share-based                                                                   
  compensation expense for the                                     150     119  
  three                                                                         
  months ended September 30, 2026                                               
  and                                                                           
  2025, respectively)                                                           
  Financial royalty asset                                          150       —  
  impairment                                                                    
  Total operating expense, net                                     279     182  
  Operating income                                                 411     427  
  Other (income)/expense                                                        
  Equity in earnings of equity                                                  
  method                                                            -9     -16  
  investees                                                                     
  Interest expense                                                  90      80  
  Other expense/(income), net                                       63     -77  
  Total other expense/(income),                                    144     -13  
  net                                                                           
  Consolidated net income before                                   267     440  
  tax                                                                           
  Income tax expense                                                 —       —  
  Consolidated net income                                          267     440  
  Net income attributable to                                       122     156  
  non-controlling interests                                                     
  Net income attributable to                                                    
  Royalty                                                          145     284  
  Pharma plc                                                                    
                                                                                
Amounts may not add due to rounding.
                                                       
  Royalty Pharma Press Release| November 4, 2026    9  
 ───────────────────────────────────────────────────── 
                                                       
                                                                                
                               Royalty Pharma plc                               
                                                                                
                                                                                
                    Selected Balance Sheet Data (unaudited)                     
                                                                                
                                                                                
                                    Table 2                                     
                                                                                
                                                                                
                                     As of September 30,    As of December 31,  
  ($ in millions)                                   2026                  2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash equivalents                          514                   619  
  Total current and non-current                                                 
  financial                                       17,079                17,063  
  royalty assets, net                                                           
  Total assets                                    19,461                19,621  
  Current portion of long-term                       997                   380  
  debt                                                                          
  Long-term debt, net of current                   7,591                 8,571  
  portion                                                                       
  Total liabilities                                9,666                 9,906  
  Total shareholders’ equity                       9,795                 9,715  
                                                                                
                                                        
  Royalty Pharma Press Release| November 4, 2026    10  
 ────────────────────────────────────────────────────── 
                                                        
                                                                                
                               Royalty Pharma plc                               
                                                                                
          Condensed Consolidated Statements of Cash Flows (unaudited)           
                                                                                
                                    Table 3                                     
                                                                                
                                                                                
                          Three Months                   Nine Months            
                       Ended September               Ended September            
                                   30,                           30,            
  ($ in millions)                 2026      2025                2026      2025  
  Cash flows from                                                               
  operating                                                                     
  activities:                                                                   
  Cash                                                                          
  collections                                                                   
  from financial                   930       882               2,660     2,439  
  royalty                                                                       
  assets                                                                        
  Cash                                                                          
  collections                                                                   
  from intangible                    0         0                   4         1  
  royalty                                                                       
  assets                                                                        
  Other royalty                                                                 
  cash                              38        29                 104        85  
  collections                                                                   
  Distributions                                                                 
  from equity                        8         —                  33        13  
  method                                                                        
  investees                                                                     
  Interest                           6         7                  18        28  
  received                                                                      
  Development-st…                                                               
  funding                          -70       -51                -193      -402  
  payments                                                                      
  Payments for                                                                  
  operating and                    -50       -34                -123      -230  
  professional                                                                  
  costs                                                                         
  Payments for                      -3        -2                 -18        -2  
  Employee EPAs                                                                 
  Interest paid                   -173      -130                -352      -270  
  Net cash                                                                      
  provided by                      686       703               2,133     1,663  
  operating                                                                     
  activities                                                                    
  Cash flows from                                                               
  investing                                                                     
  activities:                                                                   
  Acquisition of                                                                
  businesses, net                    —        -0                   —       -74  
  of cash                                                                       
  acquired                                                                      
  Distributions                                                                 
  from equity                        1         1                  30       100  
  method                                                                        
  investees                                                                     
  Purchases of                                                                  
  equity                             —         —                 -28        -4  
  securities                                                                    
  Proceeds from                                                                 
  equity                             —         —                  36         —  
  securities                                                                    
  Purchases of                                                                  
  available for                      —         —                   —       -75  
  sale debt                                                                     
  securities                                                                    
  Proceeds from                                                                 
  available for                      6         3                  14        18  
  sale debt                                                                     
  securities                                                                    
  Proceeds from                                                                 
  sales of                                                                      
  available for                      —         —                   —       511  
  sale debt                                                                     
  securities                                                                    
  Acquisitions of                                                               
  financial                       -279      -962                -982      -964  
  royalty assets                                                                
  Milestone                        -13         —                 -63      -269  
  payments                                                                      
  Other                             -0         —                  -1        -9  
  Net cash used                                                                 
  in investing                    -286      -958                -993      -766  
  activities                                                                    
  Cash flows from                                                               
  financing                                                                     
  activities:                                                                   
  Distributions                                                                 
  to legacy                                                                     
  non-controlling                  -93      -102                -257      -276  
  interests -                                                                   
  Portfolio                                                                     
  Receipts                                                                      
  Distributions                                                                 
  to continuing                    -33       -34                -108      -127  
  non-controlling                                                               
  interests                                                                     
  Dividends to                    -105       -95                -315      -284  
  shareholders                                                                  
  Repurchases of                                                                
  Class A                          -86      -146                -181    -1,147  
  ordinary shares                                                               
  Contributions                                                                 
  from legacy                        —        -0                   —         0  
  non-controlling                                                               
  interests - R&D                                                               
  Contributions                                                                 
  from                                                                          
  non-controlling                    —         0                   —         6  
  interests -                                                                   
  other                                                                         
  Proceeds from                                                                 
  revolving                         50     1,275                  50     1,275  
  credit facility                                                               
  Repayment of                                                                  
  revolving                        -50    -1,275                 -50    -1,275  
  credit facility                                                               
  Repayment of                    -380    -1,000                -380    -1,000  
  long-term debt                                                                
  Proceeds from                                                                 
  issuance of                                                                   
  long-term                          —     1,954                   —     1,954  
  debt, net of                                                                  
  discount                                                                      
  Debt issuance                      0       -14                  -2       -14  
  costs and other                                                               
  Other                             -1         —                  -2         —  
  Net cash (used                                                                
  in)/provided by                 -699       563              -1,245      -886  
  financing                                                                     
  activities                                                                    
  Net change in                                                                 
  cash and cash                   -298       307                -105        10  
  equivalents                                                                   
  Cash and cash                                                                 
  equivalents,                     812       632                 619       929  
  beginning of                                                                  
  period                                                                        
  Cash and cash                                                                 
  equivalents,                     514       939                 514       939  
  end of period                                                                 
                                                                                
EPAs: Equity Performance Awards. Amounts may not add due to rounding.
                                                        
  Royalty Pharma Press Release| November 4, 2026    11  
 ────────────────────────────────────────────────────── 
                                                        
                                                                                
                               Royalty Pharma plc                               
                                                                                
                                                                                
                  GAAP to Non-GAAP Reconciliation (unaudited)                   
                                                                                
                                                                                
                                    Table 4                                     
                                                                                
                                                                                
                                      Three Months Ended September 30,          
  ($ in millions)                                                 2026    2025  
  Net cash provided by operating                                   686     703  
  activities (GAAP)                                                             
  Adjustments:                                                                  
  Proceeds from available for sale                                              
  debt                                                               6       3  
  securities(6)                                                                 
  Distributions from equity method                                   1       1  
  investees(6)                                                                  
  Interest paid, net(6)                                            167     123  
  Development-stage funding                                         70      51  
  payments                                                                      
  Distributions to legacy                                                       
  non-controlling                                                  -93    -102  
  interests - Portfolio                                                         
  Receipts(6)                                                                   
  Payments for Employee EPAs                                         3       2  
  Adjusted EBITDA (non-GAAP)                                       840     779  
  Interest paid, net(6)                                           -167    -123  
  Portfolio Cash Flow (non-GAAP)                                   673     657  
                                                                                
EPAs: Equity Performance Awards. Amounts may not add due to rounding.
                                                        
  Royalty Pharma Press Release| November 4, 2026    12  
 ────────────────────────────────────────────────────── 
                                                        
                                                                                
                               Royalty Pharma plc                               
                                                                                
       Description of Approved Indications for Select Portfolio Therapies       
                                                                                
                                    Table 5                                     
                                                                                
                                                                                
  Cystic fibrosis franchise    Cystic fibrosis                                  
  Trelegy                      Chronic obstructive pulmonary disease and        
                               asthma                                           
  Tremfya                      Plaque psoriasis, psoriatic arthritis,           
                               ulcerative colitis and Crohn’s disease           
  Evrysdi                      Spinal muscular atrophy                          
  Tysabri                      Relapsing forms of multiple sclerosis            
  Voranigo                     Low-grade glioma                                 
  Xtandi                       Prostate cancer                                  
  Imbruvica                    Hematological malignancies and chronic graft     
                               versus host disease                              
  Cabometyx/Cometriq           Kidney, liver and thyroid cancer                 
  Imdelltra                    Small cell lung cancer                           
  Trodelvy                     Breast cancer                                    
  Spinraza                     Spinal muscular atrophy                          
  Amvuttra                     Transthyretin amyloidosis                        
  Promacta                     Chronic immune thrombocytopenia purpura and      
                               aplastic anemia                                  
                                                                                
                                                        
  Royalty Pharma Press Release| November 4, 2026    13  
 ────────────────────────────────────────────────────── 
                                                        
                                                                                
  Notes                                                                         
                                                                                
(1) Portfolio Receipts is defined above in the section entitled “Portfolio
Receipts.”

(2) Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts
minus payments for operating and professional costs. Operating and professional
costs reflect Payments for operating and professional costs from the GAAP
condensed consolidated statements of cash flows. See GAAP to Non-GAAP
reconciliation in Table 4.

(3) Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA
minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in
Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s
business that can be redeployed into value-enhancing royalty acquisitions, used
to repay debt, returned to shareholders through dividends or share purchases or
utilized for other discretionary investments.

(4) Capital Deployment is calculated as the summation of the following line
items from Royalty Pharma’s GAAP condensed consolidated statements of cash
flows: Investments in equity method investees, Purchases of available for sale
debt securities, Acquisitions of financial royalty assets, Acquisitions of other
financial assets, Milestone payments and Development-stage funding payments less
Contributions from legacy non-controlling interests - R&D .

(5) Other products primarily include Royalty Receipts on the following products:
Crysvita, Erleada, Farxiga/Onglyza, IDHIFA, Niktimvo, Nurtec ODT, Orladeyo,
Prevymis, Skytrofa, Yorvipath and distributions from the Legacy SLP Interest,
which is presented as Distributions from equity method investees on the GAAP
condensed consolidated statements of cash flows.

(6) The table below shows the line item for each adjustment and the direct
location for such line item on the GAAP condensed consolidated statements of
cash flows.
                                                                                
  Reconciling Adjustment                 Statements of Cash Flows               
                                         Classification                         
  Interest paid, net                     Operating activities(Interest          
                                         paidlessInterest received)             
  Distributions from equity method       Investing activities                   
  investees                                                                     
  Proceeds from available for sale                                              
  debt                                   Investing activities                   
  securities                                                                    
  Distributions to legacy                                                       
  non-controlling                        Financing activities                   
  interests - Portfolio Receipts                                                
                                                                                
(7) The condensed consolidated statement of operations for 2025 has been recast
to reflect the adoption of ASU 2025-07 by removing the gains previously
recognized on derivative.
                                                        
  Royalty Pharma Press Release| November 4, 2026    14  
 ────────────────────────────────────────────────────── 
                                                        

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RPRX/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.